Aptinyx

52 articles with Aptinyx

• Aptinyx to Present at Upcoming Virtual Investor Conferences - Sep 03, 2020

  9/3/2020

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will be presenting at the following virtual investor conferences:

• Aptinyx Reports Second Quarter 2020 Financial Results and Highlights

  8/13/2020

  Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020 Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon Conference call today at 5:00 p.m. ET EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financi

• Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/4/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT. A live webcast of each presentation will be available on the

• Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020

  7/30/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

• Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020

  7/8/2020

  Aptinyx to Host PTSD-Focused R&D Day on August 5 th , 2020 Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020 EVANSTON, Ill.--( BUSINESS WIRE )-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of bra

• Aptinyx to be Added to Russell 2000® Index

  6/26/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will be added as a member of the US small-cap Russell 2000® Index. The addition will be effective after the US market opens on June 29, 2020 as part of the 2020 Russell US Indexes annual reconstitution. Inclusion in the Russell 2000® Index, which remains

• Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress DisorderData readout expected by late 2020

  6/18/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 to evaluate the safety and efficacy of NYX-783 in patients with post-traumatic stress disorder (PTSD). The company anticipates reporting data from the study in late 2020. “The completi

• Aptinyx to Present at Upcoming Virtual Investor Conferences

  6/16/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences: 2020 BMO Prescription for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET and; SVB Leerink CybeRx Series: 2 nd Annual CNS Forum on Wednesda

• Aptinyx Reports First Quarter 2020 Financial Results and Highlights

  5/14/2020

  Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

• Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020

  4/30/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579 (domestic)

• Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  3/30/2020

  Aptinyx Inc. reported financial results for the fourth quarter and full year 2019 and provided updates across the company’s pipeline of novel NMDA receptor modulators.

• Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020

  3/18/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Monday, March 30, 2020 at 5:00 p.m. ET to report fourth quarter and full year 2019 financial results and discuss recent business highlights.

• Aptinyx to Present at Upcoming Investor Conferences - Feb. 19, 2020

  2/19/2020

  Aptinyx Inc. announced that company management will be presenting at the following investor conferences

• Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease

  1/30/2020

  NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease

• Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

  1/14/2020

  Aptinyx Inc. announced the closing of its public offering of 11,691,666 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.

• Aptinyx Announces Pricing of Public Offering of Common Stock

  1/10/2020

  Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering price of $3.00 per share.

• Aptinyx Announces Proposed Public Offering of Common Stock - Jan. 9, 2020

  1/9/2020

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

  12/12/2019

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference

• Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting

  12/9/2019

  The presentation is taking place today, December 9, 2019, at the Annual Meeting of the American College of Neuropsychopharmacology in Orlando, Florida.

• Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease

  12/5/2019

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease.